GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Burning Rock Biotech BNR · USD

Health Care · US listing · 🇺🇸 United States

Compare

13.32

+1.91%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Burning Rock Biotech — daily BNR Delayed
Market value
$11.7m
Last close × shares
Volume
29.5k
Shares, 19 Nov 2026

About Burning Rock Biotech

Its shares trade under the ticker BNR. It has been listed since 12 June 2020. In the fiscal year to 31 December 2025, it reported revenue of $80.5m and a net loss of $8.3m. At that date it held total assets of $122.5m and shareholders' equity of $79.9m.

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Figures and description from our data supplier, not checked against the company's own report.

More about Burning Rock Biotech →

Latest on Burning Rock Biotech

Our reporting

We have not reported on Burning Rock Biotech yet.

Next results

30 Mar 2027

Due on 30 Mar 2027. Analysts expect earnings of -0.37 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Burning Rock Biotech's ticker?

Burning Rock Biotech trades as BNR on its US listing, under ISIN US12233L1070.

What was Burning Rock Biotech's last closing price?

13.32 on 19 Nov 2026. The figure is in USD and is never converted.

When does Burning Rock Biotech next report results?

Results are expected on 17 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.